source
- Immunocore reports early data showing 70% two-year survival with brenetafusp/Kimmtrak combo in uveal melanomaImmunocore presented early clinical data on its bispecific T-cell engager combination brenetafusp and Kimmtrak in patients with uveal melanoma. The analysis, based on a subset of patients, indicat…
- Amgen’s Repatha linked to fewer heart attacks while Novartis reports seven new tumor cases in Zolgensma patientsAmgen reported that its cholesterol‑lowering drug Repatha was associated with a lower incidence of heart attacks in a recent analysis. The data suggest the therapy may provide cardiovascular benefi…